Skip Navigation
Megan McArdle

Megan McArdle - Megan McArdle is a senior editor for The Atlantic who writes about business and economics. She has worked at three start-ups, a consulting firm, an investment bank, a disaster recovery firm at Ground Zero, and The Economist. More

Megan was born and raised on the Upper West Side of Manhattan, and yes, she does enjoy her lattes, as well as the occasional extra-dry skim-milk cappuccino. Her checkered work history includes three start-ups, four years as a technology project manager for a boutique consulting firm, a summer as an associate at an investment bank, and a year spent as sort of an executive copy girl for one of the disaster-recovery firms at Ground Zero … all before the age of 30.

While working at Ground Zero, Megan started Live From the WTC, a blog focused on economics, business, and cooking. She may or may not have been the first major economics blogger, depending on whether we are allowed to throw outlying variables such as Brad Delong out of the set. From there it was but a few steps down the slippery slope to freelance journalism. She has worked in various capacities for The Economist, where she wrote about economics and oversaw the founding of Free Exchange, the magazine's economics blog. She has also maintained her own blog, Asymmetrical Information, which moved to The Atlantic, along with its owner, in August 2007.

Megan holds a bachelor's degree in English literature from the University of Pennsylvania and an M.B.A. from the University of Chicago. After a lifetime as a New Yorker, she now resides in northwest Washington, D.C., where she is still trying to figure out what one does with an apartment larger than 400 square feet.

How Much Will Insurance Companies Benefit From the Mandate?

By Megan McArdle
Sep 9 2009, 11:53 AM ET Comment

A lot of people, left and right, view the mandate as a giveaway to the insurance companies.  I'm not sure I see it.  The sweetener to get them to buy into the package, yes.  But how profitable are these extra people going to be?

The uninsured, for our purposes, consist of three groups of people:  the young and healthy, the poor and average, and the uninsurable.  This package probably makes group one worse off, group two better off (depending on where the subsidy kicks in), and group three gets the most benefit, because now they pay the same as everyone else.  (I am assuming for the nonce that this plan has what I've come to think of as the four pillars of reform:  guaranteed issue, community rating, mandate, and subsidies).  Only the first group make desirable customers, but things are being stacked so that it's hard to woo them, and them alone.

The mandate doesn't mean that insurance companies will be able to raise their average price--indeed, with the government breathing down their necks, they will face considerable pressure to lower it.  As long as there is competition in the market, the mandate probably won't help any individual firm.

Ah, but is there competition in the market?  Insurance markets tend to be highly concentrated.  If the number of firms is small enough to allow collusion, then denying customers the right of exit is indeed a license to print money.

However, even oligopolies have a hard time colluding--market outcomes with oligopolies can range from rigged quasi-monopolies (think the Big Three), to fierce competition (think Airbus and Boeing).  Which will health insurance be?

Somewhere in between, I think.  Even with highly concentrated regional markets to play in, health insurers as a group aren't particularly profitable.   I would expect to see much higher margins if the companies were really price makers.  The fear of exit should hold down some of the profits, of course.  But still.  These levels don't scream "monopoly" at me.

So there will be some advantage to having more customers:  more revenue across which to amortize your fixed costs.  Insurance does seem to have scale benefits, after all.  But a lot of those customers will be sick people who were previously uninsurable, which is not exactly a huge bargain.  And with medical technology advancing the way it is, there's no telling when some lousy scientist will invent a great new treatment that you'll have to pay some unknown, but certainly huge, sum to purchase.

Perhaps I'm wrong.  But overall, I don't see that insurance companies are getting a particularly fabulous deal out of this.  Of course, if regulation forms a big new barrier to entry--as it tends to do--that could all change . . .  


Presented by

More at The Atlantic

In Minnesota, a School District Overturns Its Policy of Silence In Minnesota, a School District Overturns Its Policy of Silence
A Neuroscientist Debunks the Myth of Musical Instinct A Neuroscientist Debunks the Myth of Musical Instinct
Adulthood, Delayed: What Has the Recession Done to Millennials? Adulthood, Delayed: The Recession and Millennials
The 10 Most Expensive Cities in the World (and How They Got That Way) The 10 Most Expensive Cities in the World
Democrats Walk Out of Tense Hearing on Contraception (Video) Democrats Walk Out of Tense Hearing on Contraception

Join the Discussion

After you comment, click Post. If you’re not already logged in you will be asked to log in or register.
blog comments powered by Disqus
Special Report
The Civil War National Portrait Gallery The Civil War
President Obama reflects on what Lincoln means to him and to America, in an introduction to our special issue. Read more ›
View All Correspondents

The Biggest Story in Photos

World Press Photo Contest 2012

Feb 15, 2012

Subscribe Now

SAVE 59%! 10 issues JUST $2.45 PER COPY

Facebook

Newsletters

Sign up to receive our free newsletters

(sample)

(sample)

(sample)

(sample)

Megan McArdle
from the Magazine

Why Companies Fail

GM’s stock price has sunk by a third since its IPO. Why is corporate turnaround so difficult…

The Graduates

Busted banking careers, crashed consultants, and shrunken incomes: the author attends her 10-year…

Romney’s Business

The Republican contender touts his business experience—but does it really matter?